Medscape Medical NewsAll articles

syngo.CT CaScoring

Siemens Medical Solutions USA, Inc. • Radiology • 05/17/2022

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

syngo.CT CaScoring is an image analysis software package that aids physicians in evaluating and documenting calcified coronary lesions from cardiac CT scans by enabling lesion marking and allocation to specific coronary arteries. It utilizes a re-trained algorithm to automatically calculate Agatston-equivalent, mass, and volume scores, providing quantitative data to support cardiovascular risk assessment and reporting.

Summary

syngo.CT CaScoring (SOMARIS/8 VB70) is an advanced post-processing software application designed to assist physicians in the evaluation and documentation of calcified coronary lesions using non-contrasted cardiac CT images. The system allows for the interactive marking of these lesions, which can then be allocated to specific coronary arteries, including the right coronary artery (RCA), left main (LM), left anterior descending (LAD), and left circumflex (CX). Its core methodology involves analyzing these CT datasets to identify and quantify calcifications, thereby providing crucial information for cardiovascular assessment. The software calculates several key metrics for each coronary artery and provides total scores: the Agatston-equivalent score, mass score, and volume score. Users can generate comprehensive paper reports incorporating this scoring data, user-documented images, cited literature, and other relevant information. Key enhancements in the SOMARIS/8 VB70 version include an algorithm for precomputing calcium scores that has been re-trained on a larger database for improved performance, and user interface modifications. Performance evaluations demonstrated that the re-trained automatic scoring algorithm provides adequate and acceptable performance for the total Agatston-equivalent score and its classification into corresponding risk categories.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Coronary Artery CalcificationCT ImagingImage Analysis SoftwareAgatston ScoreVolume ScoreMass ScoreCalcified LesionsPost-processing ApplicationCardiovascular Risk AssessmentDICOM

Device Metadata

Submission Number
K221219
Company
Siemens Medical Solutions USA, Inc.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the re-training of the CaScoring algorithm on a "larger database" specifically translate to improvements in sensitivity, specificity, or inter-observer variability for calcification detection and scoring?; What are the quantitative performance differences in Agatston, mass, and volume scores between the SOMARIS/8 VB70 and the previous VB50 version, particularly in challenging or borderline cases?; Can the syngo.CT CaScoring software differentiate between various types of calcifications (e.g., spotty vs. diffuse) or provide information on plaque morphology beyond simple scoring?; What is the impact of the "UI modifications" on the typical workflow efficiency and learning curve for new or existing users of the syngo.CT CaScoring system?; How does the system ensure consistency and accuracy in scoring when CT images are acquired using different scanner models, vendors, or low-dose protocols?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score35/100
SBOM Evidence✓ Detected in Summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials(software package)
✓ Detected
ML-BOMMachine Learning Bill of Materials(algorithm, dataset)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(server)
✓ Detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials
- Not detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of SBOM, ML-BOM, SaaSBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
syngo.CT CaScoring - Siemens Medical Solutions USA, Inc. | ESL FDA AI Device Intelligence